European Journal of Dermatology
MENUCharacterization of skin Th17 transcriptional profiles in psoriatic patients under adalimumab biotherapy Volume 27, numéro 6, November-December 2017
Auteurs
Background
1 CHU de Poitiers, 86021 Poitiers, France
2 Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, LITEC, Université de Poitiers, 86073 Poitiers, France
3 ImageUP, STIM, ERL 7368 Université de Poitiers, 86073 Poitiers, France
* Reprints
- Mots-clés : cytokine, inflammation, psoriasis, biotherapy, adalimumab
- DOI : 10.1684/ejd.2017.3127
- Page(s) : 579-89
- Année de parution : 2017
In psoriasis, a specific cytokine network has been described to play a central role in the pathophysiology of the disease. Anti-cytokine therapeutic approaches have been largely developed and TNFα constitutes the main target. Adalimumab is a human anti-TNFα monoclonal antibody that has been reported to demonstrate clinical efficacy and safety, resulting in reversal of epidermal hyperplasia and cutaneous inflammation.